Profile for Mexico Patent: 2025014073

US Patent Family Members and Approved Drugs for Mexico Patent: 2025014073

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
12,478,619	May 31, 2044	Vanda Pharms Inc	BYSANTI	milsaperidone

Key insights for pharmaceutical patentability - Mexico patent MX2025014073

Last updated: May 3, 2026

What does MX2025014073 claim, and how does it sit in the Mexico drug patent landscape?

Can MX2025014073 be mapped to a specific drug and claim set from public Mexico records?

No response can be produced. The required public record content for Mexico patent MX2025014073 (title, assignee, priority chain, grant/publication number, and the full claim text in Spanish/English) is not present in the information available in this chat. Without the actual claim text and bibliographic data, a scope analysis would risk being incorrect.

What patent landscape can be drawn for Mexico without the full bibliographic and claims text?

No response can be produced. A credible landscape requires at least: (i) the active ingredient(s) or therapeutic target disclosed by the application, (ii) the relevant priority dates, and (iii) the independent claim scope. Patent landscaping in Mexico also depends on the publication/grant status and family relationships, which cannot be validated here for MX2025014073.

Key Takeaways

• The scope and claim structure for MX2025014073 cannot be analyzed from the current inputs.
• The Mexico drug patent landscape for MX2025014073 cannot be constructed with the required accuracy (drug identity, priority chain, and claim coverage are missing).
• No actionable infringement or freedom-to-operate framing can be produced without the claim text and bibliographic record.

FAQs

1. What information is required to analyze a Mexico drug patent claim scope?
   Full bibliographic data (assignee, publication/grant number, priority chain) and complete claim text.

2. Why is the claim text essential for landscape analysis in Mexico?
   Mexican patent scope is claim-driven; without independent and dependent claim language, coverage and design-around vectors cannot be assessed.

3. Does publication number alone let you map infringement risk in Mexico?
   No. You need the claim set and family context to compare to earlier patents and later generics/biosimilars strategies.

4. How do priority dates affect the Mexico drug patent landscape?
   Priority dates determine novelty and earlier-art position for each claim set and family member across jurisdictions.

5. Can you infer drug identity from an application number?
   Not reliably; application numbering in Mexico does not expose the claimed drug or molecular matter without the record content.

References

[1] No sources were provided or available in the chat for MX2025014073.